이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

ICCAN이 암 치료 완료 및 삶의 질에 미치는 영향

2026년 9월 16일 업데이트: Memorial Sloan Kettering Cancer Center

ICCAN이 암 치료 완료 및 삶의 질에 미치는 영향에 대한 무작위 대조 시험

The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

연구 개요

연구 유형

관찰

등록 (추정된)

347

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Francesca Gany, MD, MS
  • 전화번호: 646-888-8054

연구 연락처 백업

  • 이름: Jennifer Leng, MD, MPH
  • 전화번호: 646-888-4243

연구 장소

    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • 모병
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • 연락하다:
          • Francesca Gany, MD, MS
          • 전화번호: 646-888-8054
      • Middletown, New Jersey, 미국, 07748
        • 모병
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • 연락하다:
          • Fransecsa Gany, MD, MS
          • 전화번호: 646-888-8054
      • Montvale, New Jersey, 미국, 07645
        • 모병
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • 연락하다:
          • Francesca Gany, MD, MS
          • 전화번호: 646-888-8054
    • New York
      • Brooklyn, New York, 미국, 11220
        • 모집하지 않고 적극적으로
        • Lutheran Medical Center
      • Commack, New York, 미국, 11725
        • 모병
        • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
        • 연락하다:
          • Francesca Gany, MD, MS
          • 전화번호: 646-888-8054
      • Harrison, New York, 미국, 10604
        • 모병
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • 연락하다:
          • Francesca Gany, MD, MS
          • 전화번호: 646-888-8054
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • Francesca Gany, MD, MS
          • 전화번호: 646-888-8054
        • 연락하다:
          • Jennifer Leng, MD, MPH
          • 전화번호: 646-888-4243
        • 수석 연구원:
          • Francesca Gany, MD, MS
      • New York, New York, 미국, 10035
        • 모병
        • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
        • 연락하다:
          • Francesca Gany, MD
          • 전화번호: 646-888-8054
      • New York, New York, 미국, 10031
        • 모병
        • City College of New York (Data Collection AND Data Analysis)
        • 연락하다:
      • Rockville Centre, New York, 미국, 11553
        • 모병
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • 연락하다:
          • Franscesca Gany, MD, MS
          • 전화번호: 646-888-8054
      • The Bronx, New York, 미국
        • 모집하지 않고 적극적으로
        • Lincoln Hospital and Mental Health Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Eligible cancer patients will be recruited in person by multilingual ICCAN Clinical Research Coordinators for participation in the study at Ralph Lauren Center for Cancer Care and Prevention (RLCCP), Lincoln Hospital (LH) and Lutheran Medical Center (LMC). In the event that MSK staff is not present when an eligible patient is identified. Refinement and Pilot RCT participants will be recruited through MSK Manhattan and OneMSK regional sites's.

설명

Participant Inclusion Criteria:

Patient is eligible if he/she is

  • fluent in English, Spanish, or Mandarin
  • between the ages of 21-80 years old
  • cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
  • scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
  • planning on remaining in the area for at least 1 year

Clinician is eligible if he/she:

  • Has an MD or DO degree
  • Is the treating physician providing care to a patient enrolled to the study

ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:

  • Is 18 - 85 years of age
  • Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
  • Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
  • Is treated in the NY metropolitan area
  • Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income < 200% of federal poverty level)
  • Has English or Spanish proficiency
  • Agrees to be audio-recorded

ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:

  • Is 18 - 85 years of age
  • Has stage II-III TNBC
  • Treated at MSK Manhattan or OneMSK regional sites
  • Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income < 200% of federal poverty level)
  • Has English or Spanish proficiency
  • Agrees to be audio-recorded

ICCAN-IO process evaluation study team participants only:

  • Staff member who serves as an Access Facilitator
  • Agrees to be audio-recorded

CCAN-GBM

  • Over the age of 18 (per EMR)
  • Diagnosed with Glioblastoma (per EMR)
  • Has not yet started radiation and concurrent temozolomide treatment (per EMR)
  • Has a primary neuro-oncologist at MSK (per EMR)
  • Will be undergoing radiation at MSK (per EMR)
  • Treatment plan consists of a 6-week or 3-week (hypofractionated) course of radiation and chemotherapy (per EMR)
  • Participant or caregiver is fluent in English or Spanish
  • Planning on remaining in the tri-state area during the 6 weeks or 3 weeks of radiation and chemotherapy (per self-report)
  • Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance (per EMR or self-report), demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit), and/or requests help with SDOH resources or navigation

Participant Exclusion Criteria:

Patient is ineligible if he/she is:

  • Diagnosed with Stage IV disease
  • Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
  • Has another family member already enrolled in ICCAN (as determined by patient report)

ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:

  • Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
  • Participants or family members who are participating in MSK IHCD studies related to social determinants of health

ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:

  • Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
  • Participants or family members who are participating in MSK IHCD studies related to social determinants of health at the PI's discretion

ICCAN-GBM

  • No recurrences - must be newly diagnosed glioblastoma (per EMR)
  • Patients undergoing different treatment regimens from the 15 fraction/3 week or 30 fraction/6 week course of radiation (i.e. patients undergoing 10 fractions of palliative radiation due to poor functional status) (per EMR)
  • Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms that require individual treatment) (per EMR or self-report)
  • Severe cognitive impairment or fluent aphasia as not to understand the assessment measures, interview, or informed consent, without a health care proxy or caregiver that can assist as indicated by clinician or per judgement of study staff. Completion of assessments with the help of caregivers is acceptable. (per EMR or self-report)
  • Has another family member or household member already enrolled in ICCAN (per self-report)
  • Already participated in or already completed the ICCAN program (per self-report)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Phase I: Refinement

10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Phase II, Arm 1: Usual and Customary Care (U&C)

Participants in this group will receive the same referrals on social and economic resources as ICCAN group.

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed.

Phase II, Arm 2: ICCAN-IO

Arm 2 will consist of everything in Arm 1

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Treatment completion/adherence
기간: 1 year

The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

1 year

2차 결과 측정

결과 측정
측정값 설명
기간
Quality of life
기간: 1 year

depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes

1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2012년 11월 1일

기본 완료 (추정된)

2027년 11월 1일

연구 완료 (추정된)

2027년 11월 1일

연구 등록 날짜

최초 제출

2012년 12월 3일

QC 기준을 충족하는 최초 제출

2012년 12월 3일

처음 게시됨 (추정된)

2012년 12월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 12-223

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다